secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001558370-25-007650
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock Q1 net loss $74.7M; BLA priority review set for Sept 22, 2025; cash to 2027
--------------------------------------------------------------------------------

- Net loss $74.7M ($0.67 per share) vs $56.9M in Q1 2024; no revenue.
- Cash, equivalents, securities $364.4M as of March 31, 2025; expected to fund into 2027.
- FDA accepted BLA for apitegromab with priority review; PDUFA date Sept 22, 2025.
- Topline results from Phase 2 EMBRAZE obesity trial expected June 2025.
- Leadership: David Hallal CEO; Akshay Vaishnaw President R&D; Keith Woods COO; Vikas Sinha CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000155837025007650/0001558370-25-007650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000155837025007650/srrk-20250514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-007650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer